Quantcast

Latest Anthracyclines Stories

2011-10-07 05:48:08

(Ivanhoe Newswire) -- The future looks bright for patients with HER2-positive breast cancer. A paper published in the October 6, 2011 issue of the New England Journal of Medicine (NEJM), shows that new treatment regimens, providing a lower risk of cardio toxicity, are an acceptable and effective option for patients. The new study, by the Breast Cancer International Research Group, answers a critical question raised by four previously published trials; are adjuvant anthracyclines necessary...

2011-04-02 00:00:28

MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-111 and MM-302, two candidates from the company's novel pipeline of five cancer therapeutics, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held April 2 "“ 6, 2011,...

2011-03-16 06:45:00

SYRACUSE, N.Y., March 16, 2011 /PRNewswire/ -- Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX. Preliminary tests indicate this delivery device has the potential to significantly improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast,...

2010-12-10 00:00:58

MM-111 first-in-human phase 1/ 2 and pharmacologic study in patients with advanced refractory HER2-Positive (HER2+) cancers. MM-302 pre-clinical safety and activity study of anthracycline delivery to HER2-Positive (HER2+) tumors. Cambridge, MA (Vocus/PRWEB) December 08, 2010 Merrimack Pharmaceuticals, Inc. announced today that it will present MM-111 Phase 1 clinical data at the 33rd Annual San Antonio Breast Cancer Symposium, as well as pre-clinical data on MM-302, a HER2+ tumor...

2010-11-29 07:00:00

PRINCETON, N.J., Nov. 29, 2010 /PRNewswire/ -- Celator Pharmaceuticals today announced that three abstracts on its lead program, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, will be presented at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, including a podium presentation on results from a randomized, Phase 2 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML) that compared treatment with CPX-351 to conventional cytarabine...

2010-11-15 13:00:00

COLUMBIA, Md., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, today announced financial results for the third quarter and nine months ended September 30, 2010 and addressed the progress of its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer....

2010-10-26 07:00:00

PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia (AML) in first relapse. The study, which is supported through a partnership with The Leukemia & Lymphoma Society® (LLS), achieved its target enrollment of 120...

2010-10-01 06:30:00

COLUMBIA, Md., Oct. 1 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) announced today that interim data from its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium. The abstract provided updated clinical results from the 40 mg/m2 dose cohort. Additionally the company announced that the 50 mg/m2 dose cohort has now completed enrollment. This DIGNITY study...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related